The Importance of Offering Genetic Counseling and Testing to All Persons Diagnosed With Frontotemporal Degeneration Spectrum Disorders
- 12 August 2025
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213814
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTDJournal of Neurology, Neurosurgery & Psychiatry, 2024
- Incorporating Genetic Testing Into the Care of Patients With Amyotrophic Lateral Sclerosis/Frontotemporal Degeneration Spectrum DisordersNeurology Clinical Practice, 2023
- Evidence‐based consensus guidelines for ALS genetic testing and counselingAnnals of Clinical and Translational Neurology, 2023
- Tofersen: First ApprovalDrugs, 2023
- Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyNeurotherapeutics, 2022
- The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosisBrain, 2022
- Patient and Relative Experiences and Decision-making About Genetic Testing and Counseling for Familial ALS and FTDAlzheimer Disease & Associated Disorders, 2021
- Value of systematic genetic screening of patients with amyotrophic lateral sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2021
- An update on genetic frontotemporal dementiaJournal of Neurology, 2019
- Genetic screening in sporadic ALS and FTDJournal of Neurology, Neurosurgery & Psychiatry, 2017